Second ACC Asia Conference to be held in Shanghai from November 30 to December 2, 2018

NewsGuard 100/100 Score

The American College of Cardiology will host the second ACC Asia Conference in Shanghai in collaboration with the China Cardiovascular Association and China Heart House from Nov. 30 - Dec. 2, 2018, bringing together top experts to discuss and review new, relevant cardiovascular science pertinent to the region.

Harlan Krumholz, MD, SM, FACC; Aaron D. Kugelmass, MD, FACC; and Ge Junbo, MD, PhD, FACC, will serve as co-chairs of the conference, which will provide a forum to examine evidence-based strategies as well as best practices and clinical decision-making to help the entire cardiovascular care team improve the heart health of patients in the region. During the conferences, attendees will have the opportunity to increase their knowledge in important areas such as prevention, heart failure, arrhythmias and more.

"In recent decades we've made huge advancements in the prevention and treatment of heart disease that have led to a steady decline in mortality across the globe," Kugelmass said. "However, heart disease remains the number one killer in the world, and the strategies to enhance prevention, evaluation and treatment will be different everywhere. The ACC Asia Conference aims to provide a comprehensive review of evidence-based practices and exposure to state-of-the-art updates that clinicians can take home and apply to their communities."

ACC Past President Kim Allan Williams, Sr., MD, MACC; ACC Chief Innovation Officer John Rumsfeld, MD, FACC; Jeptha Curtis, MD, FACC; Anthony Keech, MBBS; Soot Keng Ma, MD; and Catherine Otto, MD, FACC, will all serve as plenary speakers during the conference. One plenary session will feature a panel of experts discussing leadership. Conference co-chairs Kugelmass and Ge will also serve as plenary speakers.

Abstract Presentations

The following abstracts are a selection of the posters being presented. To receive embargoed copies of these abstracts, see a full list of abstracts being presented or to speak to study authors, contact Katie Glenn at [email protected]. All ACC Asia Conference 2018 abstracts are embargoed until Saturday, Dec. 1, 2018 at 8 am CST/Friday, Nov. 30, 2018 at 7 pm ET.

  • Clinical Profile of Recurrent Myocardial Infarction in the Young
  • Long-term cardiovascular outcomes after percutaneous coronary interventions in patients with acute coronary syndrome and lung cancer
  • Comparative assessment of the Framingham Risk Score and Pooled Cohort Risk Equation for prediction of cardiovascular disease risk in low resource areas: Insights from Asian rural population
  • Three Hours Ambulatory Blood Pressure Monitoring: A New Surrogate for Ambulatory Blood Pressure Assessment in the South Asian Population

Innovation Pitch Challenge

More than 15 companies from five different countries across the world applied to be a part of the Innovation Pitch Challenge at the ACC Asia Conference 2018. The challenge is part of an ongoing effort to promote engagement of cardiovascular clinicians in health care innovation and entrepreneurship.

Finalists include Biofourmis, Bosomeer Biotech Ltd., Kenzen, Shanghai Maigan Tech Co. Ltd. and Suzhou Acmedcare Medical Technology Co., Ltd. The five finalists will present their company's innovative cardiovascular product or service in front of key thought leaders on Sunday, December 2.

The Innovation Pitch Challenge is sponsored by 1M DATA.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
High blood levels of TMAO predicts chronic kidney disease risk in future